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Abstract: The global trade of honey bee hive products has raised concern about pathogen transmission.
However, the efficacy of hive products as virus vehicles is poorly understood. Here, we investigated
the transmission capacity of hive products for Deformed wing virus genotype A (DWV-A) in a
fully-crossed hoarding cage experiment and estimated the transmission risk by screening commercial
products. Western honey bee workers were provided with honey, pollen and wax either contaminated
with high (~2 × 109), medium (~1.7 × 108), low (~8 × 106) or zero (control) DWV-A genome copies. For
10 days, mortality was monitored. Then, virus titers were quantified in bee heads and 38 commercial
products using RT-qPCR. For honey and pollen, a positive association between DWV-A concentration
and mortality was observed. High concentrations always resulted in infections, medium ones in 47%
of cases and low ones in 20% of cases. No significant difference was observed between the tested
products. In commercial honey and pollen, 7.7 × 102–1.8 × 105 and 1.4 × 103–1.3 × 104 DWV-A copies
per gram were found, respectively. The results show that DWV-A transmission via hive products is
feasible. The risk of introducing novel viruses and/or strains should be considered in trade regulations
by including virus analyses for health certificates of hive products
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1. Introduction
The international trade of honey bee products increased over the past decades, thereby enhancing
chances for the spread of bee diseases [1,2]. Indeed, many honey bee pathogens have already been
discovered in traded hive products [2]. To protect the health of humans, animals and plants, most
countries joined the Terrestrial Animal Health Code (26th edition) released by the World Organization
for Animal Health (OIE) in 2017, in which the trade of animal products is also regulated. However,
amongst the honey bee pathogens, viruses are not covered by the terrestrial code due to a lack of
specific criteria (OIE 2016), even though they are frequently associated with honey bee products and
may potentially cause harmful effects [3–5]. This seems surprising because it seems most likely that
viruses are also spreading as a side effect of the worldwide trade of bee products. Regarding the
transmission of viruses, the international movement of live honey bees arguably plays the main role in
the global dispersal of bee viruses [6], facilitating the transmission between colonies. Imported bee
packages containing viral agents may act as a source of infection for other colonies in the surrounding
area (horizontal transmission). The viral particles can be horizontally transmitted in different ways,
such as when an infected bee drifts from its own colony to another [7], contact between bees during
robbing or while foraging in common food sources [8], and also by human activity, when contaminated
material is shared between colonies and apiaries [8]. The international trade of queens, in addition,
allows the introduction of viral agents inside the recipient colonies. It has been shown that queens can
hold many viruses at the same time and are able to transmit them vertically to their offspring [3,4,9–11].
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Viruses have also been detected in honey bee products such as honey, pollen and royal jelly freshly
extracted from colonies [3–5], as well as pollen pellets recently brought to colonies [5]. Moreover, the
infectivity of viruses carried by frames containing honey and pollen (bee bread) has also been shown
when colonies became infected after receiving such contaminated frames [5]. Still, the role of honey
bee hive products for the transmission of viruses in the trade scenario has not been explored in detail.
In addition to the risk of introducing novel viruses, novel strains of already established ones may
pose additional threats. Due to genetic recombination, significant changes in the viral genome may
occur resulting from the insertion of gene fragments from another viral strain during coinfection of a
host cell [12]. Indeed, recombination is increasingly recognized as a major driver of virus evolution [13].
While the high mutation rates observed in RNA viruses often generate deleterious mutations [14],
recombination events purge those deleterious mutations [15] and can often result in adaptations for the
virus, such as expanding the host range, evasion of host immunity and changes in virulence [16,17].
Although the emergence of recombinants from deformed wing virus (DWV) genotypes were
associated with increasing virulence to western honey bees, Apis mellifera [18–24], the potential of
genetic recombination is not fully understood in the context of honey bee viruses.
Ubiquitous DWV is amongst the most harmful pathogens of honey bees [6,25–28]. It can cause
clear clinical symptoms, such as crippled wings and a reduced host lifespan [27,29,30], and is a known
key driver of honey bee colony losses [31,32]. DWV is a positive sense single-stranded RNA virus
(family Iflaviridae; genus Iflavirus) [26,33] and is a recent global epidemic in honey bees [32]. The
latter is probably driven by the ectoparasitic mite, Varroa destructor, because it is a very efficient vector
of DWV. It generates a disease epidemic within the honey bee colony, which then dwindles until
it dies [26,34,35]. V. destructor have also reduced the genetic diversity of DWV [36], promoting the
spread and global distribution of DWV genotype A (DWV-A). The emergence of new genotypes, such
as DWV genotype B (DWV-B, also known as Varroa destructor virus-1), has raised concern about
their differences in virulence [22,37–39]. DWV is infecting honey bees, wild bees and probably other
arthropods [5,40] (reviewed in [41]). A better knowledge of the transmission of this particular honey
bee virus is therefore of importance, due to the considerable concern for both apiculture and nature
conservation efforts.
In this study, we investigate whether or not honey bee hive products can, in principle, act as
matrices for DWV-A transmission and how efficient they are. To achieve this goal, fully-crossed
laboratory hoarding cage experiments were conducted and complemented with a survey of DWV-A
titers in commercial bee products. Since royal jelly and propolis are known to have antimicrobial
properties [42], our study focused on honey, pollen and wax.
2. Materials and Methods
2.1. Study Set Up
In Bern, Switzerland, twelve queenright local honey bee colonies, A. mellifera, were screened for
DWV-A infections. Adult workers (N = 30) were collected from middle frames of each colony in March
and April 2015, pooled and tested for DWV-A using RT-qPCR [43]. The three colonies with the lowest
infection levels were chosen and tested again in June prior to the experiment, when they had a mean of
1.6 × 103, 3.9 × 103 and 6.1 × 103 virus copies per bee, respectively.
One sealed worker brood frame was taken from each experimental colony and placed in
an incubator at 34 ◦C and 70% relative humidity (RH) until adult emergence [44]. After 48 h,
freshly emerged workers were randomly distributed between the experimental hoarding cages. The
fully-crossed hoarding cage experiments [44] were conducted from June to August 2015 and designed
to test whether or not honey bee products spiked with DWV-A are able to induce an infection in honey
bees. To see if the efficacy in DWV-A transmission is different among the tested honey bee products,
three treatments with different initial amounts of DWV-A (high, medium and low) were used for
each product.
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Each series of experiments, corresponding to each honey bee product, consisted of four treatments:
three treatments where the honey bee product had been spiked with three different concentrations
of DWV-A (5 × 109/5 × 108/5 × 106 copies per ml for honey; 1 × 109/1 × 107/1 × 106 copies per g for
pollen; 2.5 × 108/2.5 × 106/2.5 × 105 copies per cm2 for wax; Table 1) and a non-spiked treatment with
UV-sterilized products as control. All treatments consisted of five repetitions. Each cage was equipped
with a honey solution feeder (3 mL syringe), a pollen paste feeder (modified centrifugation tube) and a
piece of wax foundation (4 cm2). Then, 30 newly emerged workers were introduced into each cage
and kept for 10 days at 30 ◦C and 70% RH in the incubator. Dead individuals were removed from
the cages daily, recorded and stored at −20 ◦C. Honey and pollen consumption was also controlled
daily and feeders refilled if required. After two days, the spiked honey and pollen products have been
consumed in all cases, resulting in an average consumption of 1 × 108 and 3.3 × 107 copies per bee for
high, 1 × 107 and 3.3 × 105 copies per bee for medium and 1 × 105 and 3.3 × 104 copies per bee for
low DWV treatment, respectively. Then the feeders were replaced with sterilized food. For the wax
product, the spiked piece of wax was available for the entire 10 days. At day 10, all remaining bees
were stored at −20 ◦C.
Table 1. Initial Deformed wing virus genotype A (DWV-A) genome copy numbers in the different
treatments. The number of DWV-A copies per contaminated honey, pollen and wax are given. For
comparison, the average number of DWV-A genome copies consumed per bee individual (virus copies
per cage divided by number of bees in cage) is also listed.
Treatment Hive Product
Group Honey Pollen Wax
High (per mL/g/cm2) 5.0 × 109 1.0 × 109 2.5 × 108
High (per bee) 1.0 × 108 3.3 × 107 3.3 × 107
Medium (per mL/g/cm2) 5.0 × 108 1.0 × 107 2.5 × 106
Medium (per bee) 1.0 × 107 3.3 × 105 3.3 × 105
Low (per mL/g/cm2) 5.0 × 106 1.0 × 106 2.5 × 105
Low (per bee) 1.0 × 105 3.3 × 104 3.3 × 104
2.2. Cage Experiment
2.2.1. Bee Product Preparation
Only honey and pollen that tested negative for DWV-A by RT-qPCR [43] was used for the
experiments. Additionally, these were irradiated with UV light for 120 min. During the UV-treatment,
the honey (25 g) was mixed by slowly rotating the honey containing tube each 30 min. A 50% (w/w) honey
solution was prepared using the UV light-treated honey and Milli-Q water (Millipore Corporation,
Billerica, MA, USA). The solution was mixed and stored at −20 ◦C until used in the experiments.
The pollen grains were crushed to a powder using a stone mortar. The grained pollen was spread
on a sheet of paper and irradiated with UV light for 120 min. Every 30 min, the pollen powder was
mixed using a sterilized spatula. The pollen paste was prepared with the following proportions: 40%
UV-light treated pollen, 50% powder sugar and 10% MilliQ water. The pollen paste was then wrapped
into aluminum foil and frozen at −20 ◦C until usage.
The wax was provided as small pieces of organic wax foundation, which was cut in square pieces
with an edge length of 20 mm. The pieces of foundation were displayed on a sheet of paper and each
side was irradiated with UV light for 30 min. After irradiation, the wax pieces were stored at −20 ◦C.
2.2.2. Propagation of DWV-A
DWV-A was propagated using standard methods [45]. Red-eyed worker pupae were microinjected
with 2 × 107 virus copies in 2 µL PBS solution (Phosphate Buffered Saline; pH 7.4) between the 2nd and
3rd integuments using a 50 µL micro syringe (Hamilton Microliter™ Syringes, Reno, Nevada, USA)
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and 30-gauge disposable needles. Pupae were incubated at 30 ◦C and collected after 6 days. Each pupa
was macerated individually in 500 µL PBS and homogenized with 100 µL chloroform using strong
vortex. After centrifugation at 13,000 rpm for 10 min, the supernatant was collected and stored at −20
◦C. DWV-A was quantified using RT-qPCR [43] and diluted to 1 × 107 copies per µL to make a stock
solution for the spiking of the bee products.
2.2.3. Spiking Bee Products with DWV-A
In a pilot study, the average amount of honey and pollen consumed by a single bee per day was
estimated. On average, one bee consumed 20+/−3.1 mg of honey solution and 16+/−3.6 mg of pollen
paste per day. The DWV-A concentration in the bee products was estimated to apply the required
number of virus copies within the first two days of the experiment for honey and pollen.
The honey solution was spiked according to the different DWV-A concentrations, keeping the
ratio of honey and water 1:1 (w/w). In the case of pollen, the DWV-A solution replaced the water in the
recipe for the pollen paste (10%). A homogenous spiking of wax was not possible because the virus
RNA would degrade at temperatures where the wax would melt. Therefore, the virus solution was
applied on the surface of the pieces of wax foundation and allowed to rest overnight for the water to
evaporate. Since bees do not consume wax, the desired virus amount was applied on the piece of wax
foundation, which was left in the cage for the entire duration of the experiment.
2.2.4. Cage Construction
The cages were clear polystyrene cups with a diameter of 63 mm and an inner volume of 75
cm3 (RIWISA AG Kunststoffwerke, Hägglingen, Switzerland). The cups were turned upside down
with the lid acting as the bottom of the cage. Each cage was fitted with three holes for ventilation
(large hole in lid covered with a mesh fabric permeable to air) as well as for holding the pollen (2 mL
micro-centrifuge tubes) and honey (2 mL plastic syringes) feeders.
2.2.5. Detection of DWV-A
To test for overt virus infection, only bee heads (N = 10 per cage) were considered for analyses [46].
The heads were removed using a scalpel sterilized using EtOH and flaming after each cut. Heads from
the same treatment were homogenized individually in 100 µL TN-Buffer (10 mM Tris HCl, 10 mM
NaCl) using a metal bead (5 mm diameter) and an electronic crushing shaker machine (Retsch Mixer
Mill MM 300, Haan, Germany). A NucleoSpin® RNA II kit (Macherey-Nagel, Oensingen, Switzerland)
was used for RNA extraction following the manufacturer’s recommendations and using 50 µL of
pooled bee head homogenates from the same cage. The purified RNA was then eluated using 60 µL of
RNase free water (Macherey-Nagel, Oensingen, Switzerland).
Reverse transcription was performed using standard protocols [32]. The concentration of RNA
was measured using a spectrophotometer (Witec NanoDrop® ND 1000 Spectrophotometer, Sursee,
Switzerland). Then, 1 µg of RNA and 0.75 µL of 100 mM hexamer primer (Microsynth AG, Balgach,
Switzerland) were heated at 70 ◦C for 5 min and then cooled down to 4 ◦C. To obtain a final volume of
25 µL, a master mix, consisting of 5 µL M-MLV Reaction Buffer (Promega, Fitchburg, Wisconsin, USA),
1.25 µL 2.5 mM dNTP Mix (Bioline, London, UK) and 1 µL 200 u/µL M-MLV reverse transcriptase
(Promega, Fitchburg, Wisconsin, USA), was added and heated to 37 ◦C for 60 min, before cooling down
to 4 ◦C. A total of 10 fold dilutions were used for the quantification assays.
Each sample was tested for DWV-A using quantitative PCR (qPCR) [32]. The qPCR was conducted
using the KAPA SYBR® Fast Universal qPCR kit (KAPA Biosystems, Wilmington, Massachusetts,
USA). Briefly, a 12 µL total volume reaction consist of 6 µL of 2x reaction buffer, 0.24 µL forward and
reverse primers each (10 µM, Table 2), 2.52 µL water and 3 µL of cDNA. The qPCR was run using an
Illumina® Eco Real-Time PCR System (Illumina, San Diego, CA, USA. The amplification conditions
were initiated by heating to 95 ◦C for three minutes in order to activate the polymerase. Then, during
each of 40 repeating cycles, the samples were heated to 95 ◦C for three seconds and cooled down to 57
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◦C for 30 s. For melting, curve analysis samples were heated to 95 ◦C for 15 s, cooled down to 55 ◦C for
another 15 s and heated from 55 ◦C to 95 ◦C while the strand dissociation was recorded.
Table 2. PCR primers used for the relative virus quantification of DWV-A.
Target Sequence (5′–3′) [bp] Ref
DWV-A
TTC ATT AAA GCC ACC TGG AAC ATC 136 [47]
TTT CCT CAT TAA GTG TGT CGT TGA
β-actin CGT TGT CCC GAG GCT CTT T 66 [48]
TGT CTC ATG AAT ACC GCA AGC
Standard curves prepared from DWV-A and A. mellifera β-Actin gene were used for virus
quantification and normalization, respectively. The standard curve dilutions (10−2 to 10−5 ng/reaction)
were prepared from purified PCR products (Table 2). Two kinds of negative controls were applied
(1: RNA-extraction control without bee sample to check for possible contamination in the reagents; 2:
PCR negative control, using water instead of cDNA template).
2.3. Survey of DWV-A in Commercial Honey and Pollen Products
Honey (N = 34) and pollen (N = 5) products were acquired from a variety of local Swiss grocery
stores. The honeys originated from all continents except Antarctica and the pollen originated from
Spain. For extracting RNA from honey and pollen, 120 mg of these bee products and 200 µL of
TN-Buffer were mixed thoroughly by using a shaker (Retsch Mixer Mill MM 300, Haan, Germany) and
a metal bead (2 mm diameter) that was put inside the sample tube. After shaking, the sample was
centrifuged for 5 min at 14,000 rpm. 50 µL of the supernatant were then used for the RNA extraction
following the NucleoSpin® RNA II kit (Macherey-Nagel, Oensingen, Switzerland) protocol. Reverse
transcription as well as qPCR [32] were conducted as described above.
2.4. Statistical Analyses
The statistical analyses were performed using the NCSS statistical software version 10. Since
the Kolmogorov-Smirnov test rejected normality in all the used data sets (Test value = 0.289 for virus
copies data, 0.305 for delta DWV-A data, 0.214 for cage infection data and 0.246 for mortality data),
non-parametric tests were used. The sample size was the number of cages per treatment (N = 5)
because considering each bee individually would result in pseudo replications [39]. For all tests a
critical p-value of 0.05 was used.
Using the log rank test with a Bonferroni correction, we checked each bee product experiment for
significant differences in mortality between treatments of different DWV-A concentrations. Bees from
all five cages underlying the same treatment were integrated for the survival analyses. There were 150
bees per treatment and the survival was recorded for 10 days.
The Kruskal-Wallis multiple-comparison z-value test with Bonferroni correction was used to test
for differences in DWV-A titers between high, medium and low DWV-A treatments as well as control
treatments with sterilized products. As before, all bees from the same treatment were integrated to
one population.
To compare the DWV-A transmission efficacy between different honey bee products a ∆ DWV-A
level was calculated. The average number of DWV-A copies taken up by the bees during the experiment
was subtracted from the detected DWV-A copies in the heads. Thus the ∆-DWV-A value was a measure
for DWV-A replication within the bees. For the analysis, all bees receiving virus copies via the same
honey bee product were integrated. In addition, here the Kruskal-Wallis multiple-comparison z-value
with Bonferroni correction was used.




With the exception of one outlier, death rates of less than 15% mortality during the ten-day
experiments were observed in all control cages. In the case of the honey assays, the mortality was
significantly higher at the high DWV-A treatment compared to all lower DWV-A concentrations
and the control (Log Rank test, p < 0.0001 per each pair-wise comparison). In the pollen assays, the
control cages had significantly lower death rates than those of high (p < 0.0001) and medium (p =
0.0005) DWV-A treatment. Concerning wax, no significant differences in mortality between different
treatments were found (Figure 1).
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Figure 1. Kaplan-Meier survival plots of caged honey bee workers over the experimental period for
each bee product ((A) honey, (B) pollen and (C) wax) with high, medium and low initial DWV-A
concentrations. Survival for each treatment was pooled from 5 cages with 30 bees each. Significant
differences are indicated by different letters (a,b).
3.1.2. DWV-A Infection Levels
While the Kruskal-Wallis test indicated significantly higher DWV-A titers in the heads of bees
from high DWV-A treatments compared to bees from control treatments in honey (z = 2.83), pollen (z =
3.64) and wax (z = 2.89), the high DWV-A treatments also showed significantly higher DWV-A titers
compared to the low DWV-A treatments in the case of honey (z = 2.78) and pollen (z = 2.83) treatments.
The critical significance level of the z-value, concerning Bonferroni correction, was 2.64 with the
p-value set at 0.05. As in the survival curves, the correlation between initial DWV-A concentration and
mortality or virus titers, respectively, was the strongest in pollen and the weakest in wax (Figure 2).
According to the detected amount of DWV-A in their heads, a significant bimodal distribution
(Kolmogorov-Smirnov normality, test value = 0.289), was found (Figure 3). The group with the lower
DWV-A showed between 5 × 103 and 5 × 105 (median = 2.2 × 104) copies per bee, while the group
with the higher DWV-A showed between 1 × 109 and 2 × 1011 (median = 2.0 × 1010) copies per bee.
Bees from the higher DWV-A group had significantly more viruses (between one to five orders of
magnitude) than the initial fed amount (from 3.3 × 104 to 1 × 108 copies per bee; Kruskal-Wallis test,
z-value = 5.65). Therefore, virus replication can be considered to occur in those bees.
Regarding the frequency of infection, the number of bee cages that showed an infection as defined
above was different depending on the treatment. High DWV-A treatment resulted in an infection of all
cages independent of the bee product. At the medium DWV-A treatment, there were two out of five
infected cages in honey and pollen each, while there were three in wax. The largest difference was seen
at low virus concentrations. There was one infected cage in the case of honey, two in the case of wax
while no cages were infected in the case of pollen.
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The comparison between the different bee products showed no significant differences (z = 0.38 for
honey and pollen, 1.88 for honey and wax and 1.50 for pollen and wax) in virus titers between the
different honey bee products (Figure 4).
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3.2. Survey of DWV-A in Commercial Honey and Pollen
In all honey and pollen samples, the detected amount of DWV-A was low. In honey, between 7.6
× 102 a d 1.8 × 105 virus copie with a median of 1.2 × 104 virus copies per gram were d tect d. In
pollen, between 1.4 × 103 and 1.2 × 104 virus copies with a median of 3.5 × 103 virus copi s per gram
were detected (Figure 5).
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Similar to honey, the high DWV-A treatment affects mortality in the pollen assays. Moreover, 
mortality in the medium treatment was also higher than in controls. On the other hand, no significant 
difference in mortality was found between the low treatment and the control, which is consistent 
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In the case of wax assays, no differences in mortality were found among different DWV-A 
treatments and controls. One possible reason could be that wax does not serve as a food resource, so 
the oral pathway is somehow different in comparison to honey and pollen. 
Figure 5. Survey results for commercial honey and pollen. DWV-A copies per mg in 34 commercial
honey and 5 pollen samples are shown. Even though a few honey samples showed higher DWV-A titers,
no significant difference between the two products was found (Kruskal-Wallis multiple-comparison
z-value test, z-value = 1.9324, p > 0.05).
4. Discussion
Our results clearly show that DWV-A transmission via hive products is feasible. The data also
show that mortality increases w en honey bees are fed with higher titers of DWV-A via oney and
pollen, but not via wax. DWV-A infecti was detected in all cages from the high treatment (fed with
at least 3.3 × 107 copies per bee), irrespective of th tested bee product. Only very small amounts of
DWV-A were detected in the commercial bee products.
4.1. DWV-A Transmission Experiment
4.1.1. Survival and DWV-A Titers in Caged Bees
The surviv l plot shows hat only the high DWV-A treatment affects mortality in the honey
treatments. Moreover, this treatment resulted in high DWV-A infections in all cages. This suggests
an association between mortality and DWV-A infection by oral consumption of high DWV-A titers
(1.0 × 108 virus copies per bee) via honey. In contrast, mortality was not different from the controls at
the medium and low treatments, despite the occurrence of high DWV-A titers in some of those cages.
Similar to honey, the high DWV-A treatment affects mortality in the pollen assays. Moreover, mortality
in the medium treatment was also higher than in controls. On the other hand, no significant difference
in mortality was found between the low treatment and the control, which is consistent with the low
DWV-A titers detected in the bee heads from the pollen low treatment.
In the case of wax assays, no differences in mortality were found among different DWV-A
treatments and controls. One possible reason could be that wax does not serve as a food resource, so
the oral pathway is somehow different in comparison to honey and pollen.
Vet. Sci. 2020, 7, 96 11 of 16
4.1.2. Data Structure of Detected DWV-A in Bee Heads
Looking at the detected DWV-A titers in the bee heads, there was one pattern that could be
observed across all bee products and treatments, including the controls. All bees could be divided into
either a high (median = 2.0 × 1010 copies per bee) or a low (median = 2.2 × 104 copies per bee) DWV-A
titer group (Figure 3). There was a distinct gap between 5 × 105 and 1 × 109 DWV-A copies per bee,
with not a single sample in this range. The highest DWV-A amount fed in the experiment was 1 × 108
copies per bee considering that each bee had fed the same (average) amount of spiked bee product. If
that assumption is true, all bees from the group with high detected virus titers (>1 × 109 copies/bee)
had at least one order of magnitude more virus copies in their heads than the maximal amount of virus
that they had taken up during the experiment. Therefore, all bees with a DWV-A amount of at least 1
× 109 copies can be considered as having experienced DWV-A replication and thus an overt infection.
In contrast, there were samples in the group of low detected DWV-A titers that showed considerably
less DWV-A copies than have been fed, indicating that infection does not always occur. Since up to 5 ×
105 DWV-A copies per bee were found even in bees from the negative control, these virus titers are
likely to represent DWV-A cover infection levels.
4.1.3. Product Comparison
The honey treatments were spiked with more virus copies compared to pollen and wax, because
the different physical properties of the hive products only enabled a certain maximum of treatment
solution to be absorbed. Hence, a direct comparison of the tested hive products for viral titers was
not feasible. Instead, we compared the DWV-A transmission efficacy between the products using
a ∆-DWV-A level as a measure for virus replication within the bees. A significant difference of
transmission efficacy between honey, pollen and wax was not found. Even though the obtained results
from different bee products are mostly similar, there might be a trend that wax transmits DWV-A easier
than honey and pollen. This can be seen in Figure 4, where the median of wax is the highest. That
implies that there was more virus replication in the wax treatments, compared to the two other bee
products. Indeed, the high levels of the detected virus in the low DWV-A treatment of wax were not
significantly different from the high DWV-A treatment, which stands in contrast to the observations
of the other products. This might be a clue for a lower DWV-A threshold for an infection via wax.
Another indicator can be found when looking at the number of individual cages in which DWV-A
replication occurred. In the case of wax, replication took place in two out of five cages in low DWV-A
treatment and in three out of five cages in medium DWV-A treatment (number of infected cages: honey
low = 1; pollen low = 0; honey medium = 2; pollen medium = 2). However, the impression that
wax might be the most efficient matrix of all tested products could also have a methodical reason: in
contrast to the honey and pollen assays, where bees consumed the spiked products during 48 h, the
spiked pieces of wax were in contact with the bees for 10 days. The amount of virus was similar in the
wax compared to the pollen and honey assays, but the virus was highly concentrated on the surface
due to an inhomogeneous DWV-A distribution. Apart from that, a different transmission route, such
as topical transmission [49], may produce different effects in the host parasite interactions since wax
does not serve as food for honey bees.
4.2. Survey of DWV-A in Commercial Honey and Pollen
Detected amounts of DWV-A in commercially available honey and pollen were relatively low
(1.8 × 105 and 1.2 × 104 copies per gram, the highest values, respectively). However, Mazzei and
colleagues [50] found up to 3.0 × 106 virus copies per gram in pollen samples freshly collected by
honey bee workers. This amount is 230-fold higher compared to our highest value in pollen. One
reason for this difference could be the quick degradation of DWV-A particles at room temperature [51].
In the same line, Graystock and colleagues [52] only detected DWV-A in 2 out of 25 samples of pollen
provided as food for bumblebee colonies.
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Transmission Risk Under Realistic Conditions
Overall, the transmission risk of DWV-A via bee products under realistic conditions is not very
high. Nevertheless, it is possible and should be considered. In the case of pollen, the cage experiment
shows that a transmission and infection, defined by detection of high DWV-A titers, can only take
place if the supplied DWV-A concentration lies between 1 × 106 and 1 × 107 copies per gram. However,
in all samples tested in the survey of commercial pollen none reached a concentration in that range.
Therefore, the risk of DWV-A to produce infection when transmitted via pollen is considered minimal.
By contrast, honey appears more efficient as a potential matrix for DWV-A transmission. With
one out of five cages infected at a concentration of 5 × 106 virus copies per milliliter, a transmission is
possible even at lower concentrations. Since we had no test point at lower concentrations, the minimal
infectious dose of DWV-A via honey was not clearly defined. However, there were 3 out of the 33
honey samples that showed concentrations of more than 1 × 105 virus copies per milliliter in the
commercial honey survey. Thus, those three samples were very close to the concentration that induced
infection in one out of five cages. Based on these data, the risk of DWV-A transmission via honey
under realistic conditions is 3/33 × 5 which is around 2% with the transmission threshold set at 1 ×
105 DWV-A copies per milliliter. It is known that viral particles exposed to environmental conditions
(e.g., humidity and heat) may quickly deteriorate [51,53,54]. This variable has not been thoroughly
tested in this study. Nevertheless, it has been shown that viruses contained in frames with honey and
bee bread remain infective even after been stored by six months at room temperature [5]. Since honey
and bee bread stored in frames may represent a different kind of matrices than commercial processed
honey and pollen products, data regarding the infectability of DWV in such commercial processed
hive products stored for longer periods of time are needed. Until then, even though the estimated
infection risk of 2% appears to be rather small, it is only a question of time before an infection occurs,
especially if bees consume large amounts of imported honey. Moritz and Erler [55] observed a positive
correlation between the amount of honey produced per colony and the amount of honey imports.
Thus, they are considering the possibility of relabeling imported honey to locally produced honey. This
illegal relabeling might be disguised by feeding the imported honey to local bee colonies. In that case,
local bees would consume huge amounts of imported and possibly contaminated honey, which would
increase the chance of infection dramatically.
For wax as a matrix, we have no data for realistic DWV-A concentrations of commercial products.
That makes it impossible to evaluate a realistic transmission risk. However, wax is often heated during
commercial processing and this may inactivate viruses, thereby decreasing the role of wax foundation
as a virus carrier in the global trade scenario. By contrast, wax showed some transmission potential in
the cage experiments and should thus also be considered as a potentially effective DWV-A vehicle, e.g.,
as a result of the common apicultural practice of exchanging non-processed combs between colonies.
As DWV is ubiquitous in most continents, a major concern should be the introduction of novel,
potentially more virulent strains. Genetic recombination between different strains may indeed result
in new viral variants with enhanced virulence. For example, distribution of DWV-B (also known as
VDV-1) has expanded over the last decade [56] and recombination events with DWV-A appear to
be frequent [18–23]. Moreover, the selection of a virulent recombinant variant between DWV-A and
DWV-B has been already reported [23]. However, due to the potent role of V. destructor as a virus
vector [35], it appears as if a recombinant DWV variant with lower virulence has been selected to
optimize its transmission by V. destructor [57]. Therefore, more studies are necessary to assess the real
impact of DWV genetic recombination on the emergence of potentially more virulent strains.
Risk is composed of the probability of occurrence and the damage caused if that undesired event
actually occurs [58]. Therefore, the potential of hive products for virus transmission reported here
should be considered, even though the probability of occurrence is probably rather low. Indeed, the
potential damage resulting from novel viral strains could obviously be severe. Therefore, the potential
of hive products for virus transmission should be considered in daily beekeeping practice. For example,
it appears very risky to feed cheap honey to colonies, which is unfortunately a common practice of
Vet. Sci. 2020, 7, 96 13 of 16
some beekeepers. A sustainable way to limit the risk effectively would be to include virus analyses in
health certificates for import and export of hive products.
5. Conclusions
Our data clearly show that transmission of DWV-A via hive products is feasible. Since there are
currently no regulations aiming to limit the spread of viruses due to global trade, the results are calling
for respective mitigation measures, i.e., health certificates for hive products.
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